{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:09:42Z","timestamp":1788282582147,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic cancer has been considered uniformly fatal in the past with very poor outcomes for most cancer sites. However, novel systemic and targeted therapies have rendered unique responses with longer survival across several cancer types and metastatic sites. In addition, improved surgical experience and safety with good outcomes has made metastasectomy as an alternative curative-intent treatment across multiple organ sites. The pancreas is an uncommon site for metastasis, even if &gt;30 different primary tumor entities have been described to metastasize to the pancreas. More than half of all resected metastasis in the pancreas are from renal cell carcinoma (RCC). RCC demonstrates a particular capacity to metastasize to nearly any site in the body\u2014including uncommon sites like the tongue, salivary glands, spleen, testes, and pancreas\u2014and, have remarkable plasticity and specific molecular trajectories with clinical implications. Cancer cells have a propensity to metastasize to specific organ sites, such as the lungs, liver or skeleton, called \u201corganotropism\u201d and the inherent tumor biology as well as the concept of \u2018oligometastatic\u2019 disease is still controversial and conflicting. Pancreatic metastasis has a very different biology from other RCC metastatic sites. Clinical observations suggest an indolent biology that warrants further investigation. Survival times are very long and approaching up to 10\u00a0years in recent series. In this paper we discuss the specific situation of pancreatic metastasis from RCC, the relation to oligometastasis and organotropism and how this can be viewed as a model to better understand cancer biology.<\/jats:p>","DOI":"10.1007\/s10585-025-10359-w","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:16:50Z","timestamp":1751519810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Renal cell carcinoma with metastasis to the pancreas: a model for oligometastasis, oligoprogression and metastatic organotropism"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-4354","authenticated-orcid":false,"given":"Kjetil","family":"S\u00f8reide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elen Martine","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Nyre","family":"Vigmostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"10359_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1245\/s10434-007-9782-0","volume":"15","author":"A Zerbi","year":"2008","unstructured":"Zerbi A, Ortolano E, Balzano G, Borri A, Beneduce AA, Di Carlo V (2008) Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol 15:1161\u20131168","journal-title":"Ann Surg Oncol"},{"key":"10359_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/00365521.2023.2286911","volume":"59","author":"KA Riemenschneider","year":"2024","unstructured":"Riemenschneider KA, Farooqui W, Penninga L, Storkholm JH, Hansen CP (2024) The results of surgery for renal cell carcinoma metastases of the pancreas. Scand J Gastroenterol 59:354\u2013360","journal-title":"Scand J Gastroenterol"},{"key":"10359_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pan.2023.11.014","volume":"24","author":"S Hajibandeh","year":"2024","unstructured":"Hajibandeh S, Hajibandeh S, Romman S, Ghassemi N, Evans D, Laing RW, Durkin D, Athwal TS (2024) Pancreatic resection for metastasis from renal cell carcinoma: a single institution experience and meta-analysis of survival outcomes. Pancreatology 24:160\u2013168","journal-title":"Pancreatology"},{"key":"10359_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.107960","volume":"50","author":"M Boubaddi","year":"2024","unstructured":"Boubaddi M, Marichez A, Adam JP, Chiche L, Laurent C (2024) Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma. Eur J Surg Oncol 50:107960","journal-title":"Eur J Surg Oncol"},{"key":"10359_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.2020.38.6_suppl.642","volume":"38","author":"S Dudani","year":"2020","unstructured":"Dudani S, Velasco Gd, Wells C, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Hansen AR, Bjarnason GA et al (2020) Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): results from the International mRCC Database Consortium (IMDC). J Clin Oncol 38:642\u2013642","journal-title":"J Clin Oncol"},{"key":"10359_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102018","volume":"60","author":"C Duarte","year":"2023","unstructured":"Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R et al (2023) Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study. EClinicalMedicine 60:102018","journal-title":"EClinicalMedicine"},{"key":"10359_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12894-025-01802-x","volume":"25","author":"K Hasselgren","year":"2025","unstructured":"Hasselgren K, Bencherki A, Short J, Bendler A, Mehriban Y, Fredrikson M, Lundgren PO, Holmbom M (2025) Survival outcomes and risk factors for liver and pancreatic metastases in renal cell carcinoma after curative nephrectomy. BMC Urol 25:123","journal-title":"BMC Urol"},{"key":"10359_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/CMAR.S484947","volume":"17","author":"K Puco","year":"2025","unstructured":"Puco K, Notland CS, Szulkin R, Jonasson C, Beisland C, Johannesen TB, Solli O, Oldenburg J, Heinrich D (2025) Overall survival of patients with metastatic renal cell carcinoma following the introduction of targeted and immunotherapies: a norwegian retrospective, real-world registry data study (RECON3). Cancer Manag Res 17:103\u2013112","journal-title":"Cancer Manag Res"},{"key":"10359_CR9","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794\u20135799","journal-title":"J Clin Oncol"},{"key":"10359_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, Powles T, Szabados B (2024) Renal cell carcinoma. Lancet 404:476\u2013491","journal-title":"Lancet"},{"key":"10359_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(24)00268-7","volume":"25","author":"D Borchiellini","year":"2024","unstructured":"Borchiellini D, Bensalah K (2024) Perioperative immunotherapy in renal cell carcinoma. Lancet Oncol 25:950\u2013951","journal-title":"Lancet Oncol"},{"key":"10359_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ (2017) Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med 376:354\u2013366","journal-title":"N Engl J Med"},{"key":"10359_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.05.007","author":"DK Leung","year":"2025","unstructured":"Leung DK, Wong CH, Ko IC, Siu BW, Liu AQ, Meng HY, Yuen SK, Chen S, Hu Q, Ng CF, Teoh JYC (2025) Global trends in the incidence, mortality, and risk-attributable deaths for prostate, bladder, and kidney cancers: a systematic analysis from the global burden of disease study 2021. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.05.007","journal-title":"Eur Urol Oncol"},{"key":"10359_CR14","first-page":"177","volume":"104","author":"E Jenssen","year":"1952","unstructured":"Jenssen E (1952) A metastatic hypernephroma to the pancreas. Acta Chir Scand 104:177\u2013180","journal-title":"Acta Chir Scand"},{"key":"10359_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1245\/s10434-019-07258-2","volume":"26","author":"Q Huang","year":"2019","unstructured":"Huang Q, Zhou H, Liu C, Jin K, Fan K, Cheng H, Fan Z, Yang C, Liu L, Long J et al (2019) Surgical resection for metastatic tumors in the pancreas: a single-center experience and systematic review. Ann Surg Oncol 26:1649\u20131656","journal-title":"Ann Surg Oncol"},{"key":"10359_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ejso.2013.12.022","volume":"40","author":"H Adler","year":"2014","unstructured":"Adler H, Redmond CE, Heneghan HM, Swan N, Maguire D, Traynor O, Hoti E, Geoghegan JG, Conlon KC (2014) Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol 40:379\u2013386","journal-title":"Eur J Surg Oncol"},{"key":"10359_CR17","first-page":"337","volume":"71","author":"C Sperti","year":"2016","unstructured":"Sperti C, Pozza G, Brazzale AR, Buratin A, Moletta L, Beltrame V, Valmasoni M (2016) Metastatic tumors to the pancreas: a systematic review and meta-analysis. Minerva Chir 71:337\u2013344","journal-title":"Minerva Chir"},{"key":"10359_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1470-2045(09)70065-8","volume":"10","author":"S Reddy","year":"2009","unstructured":"Reddy S, Wolfgang CL (2009) The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10:287\u2013293","journal-title":"Lancet Oncol"},{"key":"10359_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1245\/s10434-016-5619-z","volume":"24","author":"SR Lee","year":"2017","unstructured":"Lee SR, Gemenetzis G, Cooper M, Javed AA, Cameron JL, Wolfgang CL, Eckhauser FE, He J, Weiss MJ (2017) Long-term outcomes of 98 surgically resected metastatic tumors in the pancreas. Ann Surg Oncol 24:801\u2013807","journal-title":"Ann Surg Oncol"},{"key":"10359_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21869","volume":"4","author":"S Dudani","year":"2021","unstructured":"Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A et al (2021) Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 4:e2021869","journal-title":"JAMA Netw Open"},{"key":"10359_CR21","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1245\/s10434-014-4256-7","volume":"22","author":"M Santoni","year":"2015","unstructured":"Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L et al (2015) Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 22:2094\u20132100","journal-title":"Ann Surg Oncol"},{"key":"10359_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ejso.2022.11.094","volume":"49","author":"H Hara","year":"2023","unstructured":"Hara H, Kawamoto T, Fukase N, Sawada R, Fujiwara S, Yahiro S, Miyamoto T, Terakawa T, Mifune Y, Hoshino Y et al (2023) Outcomes of palliative surgery for bone metastasis of metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol 49:928\u2013933","journal-title":"Eur J Surg Oncol"},{"key":"10359_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","volume":"5","author":"A Bex","year":"2019","unstructured":"Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar LM, Wood L, van Melick HHE et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the surtime randomized clinical trial. JAMA Oncol 5:164\u2013170","journal-title":"JAMA Oncol"},{"key":"10359_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","volume":"379","author":"A M\u00e9jean","year":"2018","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417\u2013427","journal-title":"N Engl J Med"},{"key":"10359_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","volume":"24","author":"L Iisager","year":"2024","unstructured":"Iisager L, Ahrenfeldt J, Donskov F, Ljungberg B, Bex A, Lund L, Lyskj\u00e6r I, Fristrup N (2024) Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. BMC Cancer 24:260","journal-title":"BMC Cancer"},{"key":"10359_CR26","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P et al (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol 24:e121\u2013e132","journal-title":"Lancet Oncol"},{"key":"10359_CR27","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S1470-2045(24)00023-8","volume":"25","author":"G Marvaso","year":"2024","unstructured":"Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U et al (2024) Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. Lancet Oncol 25:e193\u2013e204","journal-title":"Lancet Oncol"},{"key":"10359_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390:1359\u20131371","journal-title":"N Engl J Med"},{"key":"10359_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-022-00592-3","volume":"19","author":"A Ingels","year":"2022","unstructured":"Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara \u00d6, Klatte T, Kriegmair MC et al (2022) Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 19:391\u2013418","journal-title":"Nat Rev Urol"},{"key":"10359_CR30","doi-asserted-by":"publisher","first-page":"373.e379","DOI":"10.1016\/j.urolonc.2024.06.006","volume":"42","author":"M Kippenberger","year":"2024","unstructured":"Kippenberger M, Sch\u00f6nberg G, Kaczorowski A, Schneider F, B\u00f6ning S, Sun A, Schwab C, G\u00f6rtz M, Sch\u00fctz V, Stenzinger A et al (2024) Immune landscape of renal cell carcinoma with metastasis to the pancreas. Urol Oncol 42:373.e379-373.e317","journal-title":"Urol Oncol"},{"key":"10359_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","volume":"42","author":"RM Saliby","year":"2024","unstructured":"Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K et al (2024) Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 42:732\u2013735","journal-title":"Cancer Cell"},{"key":"10359_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/COC.0000000000000866","volume":"44","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, Stoltzfus KC, Jones BM, Gusani NJ, Walter V, Wang M, Trifiletti DM, Siva S, Louie AV, Zaorsky NG (2021) Trends in diagnosis and treatment of metastatic cancer in the United States. Am J Clin Oncol 44:572\u2013579","journal-title":"Am J Clin Oncol"},{"key":"10359_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"key":"10359_CR34","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1200\/JCO.22.01482","volume":"40","author":"W Liu","year":"2022","unstructured":"Liu W, Bahig H, Palma DA (2022) Oligometastases: emerging evidence. J Clin Oncol 40:4250\u20134260","journal-title":"J Clin Oncol"},{"key":"10359_CR35","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28","journal-title":"Lancet Oncol"},{"key":"10359_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MOU.0000000000001184","volume":"34","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Miszczyk M, Matsukawa A, Nyir\u00e1dy P, Shariat SF, Rajwa P (2024) Defining oligometastatic state in uro-oncological cancers. Curr Opin Urol 34:261\u2013265","journal-title":"Curr Opin Urol"},{"key":"10359_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOU.0000000000001179","volume":"34","author":"G Francolini","year":"2024","unstructured":"Francolini G, Campi R, Ciccarese C (2024) Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era. Curr Opin Urol 34:300\u2013306","journal-title":"Curr Opin Urol"},{"key":"10359_CR38","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1245\/s10434-022-11351-4","volume":"29","author":"D Wankhede","year":"2022","unstructured":"Wankhede D, Grover S (2022) Outcomes after curative metastasectomy for patients with malignant melanoma: a systematic review and meta-analysis. Ann Surg Oncol 29:3709\u20133723","journal-title":"Ann Surg Oncol"},{"key":"10359_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.pan.2015.03.014","volume":"15","author":"MR DeLuzio","year":"2015","unstructured":"DeLuzio MR, Moores C, Dhamija A, Wang Z, Cha C, Boffa DJ, Detterbeck FC, Kim AW (2015) Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients\u2013a systematic review. Pancreatology 15:456\u2013462","journal-title":"Pancreatology"},{"key":"10359_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","volume":"49","author":"Y Gao","year":"2019","unstructured":"Gao Y, Bado I, Wang H, Zhang W, Rosen JM, Zhang XH (2019) Metastasis organotropism: redefining the congenial soil. Dev Cell 49:375\u2013391","journal-title":"Dev Cell"},{"key":"10359_CR41","doi-asserted-by":"publisher","first-page":"C971","DOI":"10.1152\/ajpcell.00348.2022","volume":"324","author":"D Sulekha Suresh","year":"2023","unstructured":"Sulekha Suresh D, Guruvayoorappan C (2023) Molecular principles of tissue invasion and metastasis. Am J Physiol Cell Physiol 324:C971-c991","journal-title":"Am J Physiol Cell Physiol"},{"key":"10359_CR42","doi-asserted-by":"publisher","first-page":"1358786","DOI":"10.3389\/fonc.2024.1358786","volume":"14","author":"M Carrolo","year":"2024","unstructured":"Carrolo M, Miranda JAI, Vilhais G, Quintela A, Sousa MFE, Costa DA, Pinto FR (2024) Metastatic organotropism: a brief overview. Front Oncol 14:1358786","journal-title":"Front Oncol"},{"key":"10359_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ccell.2020.10.021","volume":"38","author":"J Brugarolas","year":"2020","unstructured":"Brugarolas J, Rajaram S, Christie A, Kapur P (2020) The evolution of angiogenic and inflamed tumors: the renal cancer paradigm. Cancer Cell 38:771\u2013773","journal-title":"Cancer Cell"},{"key":"10359_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113534","volume":"199","author":"F Carneiro","year":"2024","unstructured":"Carneiro F, Vinceneux A, Larroquette M, Rony M, Carril L, Laguerre B, Blazevic I, Bartelemy P, Teyssonneau D, Goujon M et al (2024) Gastrointestinal metastases in renal cell carcinoma: a retrospective multicenter GETUG (Groupe d\u2019\u00c9tude des Tumeurs Uro-G\u00e9nitales) study. Eur J Cancer 199:113534","journal-title":"Eur J Cancer"},{"key":"10359_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.trecan.2024.11.012","volume":"11","author":"KJ Dunbar","year":"2025","unstructured":"Dunbar KJ, Efe G, Cunningham K, Esquea E, Navaridas R, Rustgi AK (2025) Regulation of metastatic organotropism. Trends Cancer 11:216\u2013231","journal-title":"Trends Cancer"},{"key":"10359_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, Luo P, Cheng Q, Xu H, Han X (2024) Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther 9:270","journal-title":"Signal Transduct Target Ther"},{"key":"10359_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, Yuan W, Gu X, Hu J, Yang S (2024) Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther 9:236","journal-title":"Signal Transduct Target Ther"},{"key":"10359_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-025-02315-9","volume":"24","author":"X Zhou","year":"2025","unstructured":"Zhou X, Li R, Lai M, Lai C (2025) Exploring molecular and cellular mechanisms of pre-metastatic niche in renal cell carcinoma. Mol Cancer 24:121","journal-title":"Mol Cancer"},{"key":"10359_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semcancer.2023.05.003","volume":"93","author":"M Hu","year":"2023","unstructured":"Hu M, Kenific CM, Boudreau N, Lyden D (2023) Tumor-derived nanoseeds condition the soil for metastatic organotropism. Semin Cancer Biol 93:70\u201382","journal-title":"Semin Cancer Biol"},{"key":"10359_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4143\/crt.2022.1460","volume":"55","author":"VS Tan","year":"2023","unstructured":"Tan VS, Palma DA (2023) Top ten lessons learned from trials in oligometastatic cancers. Cancer Res Treat 55:5\u201314","journal-title":"Cancer Res Treat"},{"key":"10359_CR51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.hpb.2018.10.006","volume":"21","author":"K S\u00f8reide","year":"2019","unstructured":"S\u00f8reide K, Olsen F, Nymo LS, Kleive D, Lassen K (2019) A nationwide cohort study of resection rates and short-term outcomes in open and laparoscopic distal pancreatectomy. HPB (Oxford) 21:669\u2013678","journal-title":"HPB (Oxford)"},{"key":"10359_CR52","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.pan.2019.07.047","volume":"19","author":"K S\u00f8reide","year":"2019","unstructured":"S\u00f8reide K, Nymo LS, Kleive D, Olsen F, Lassen K (2019) Variation in use of open and laparoscopic distal pancreatectomy and associated outcome metrics in a universal health care system. Pancreatology 19:880\u2013887","journal-title":"Pancreatology"},{"key":"10359_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejso.2021.08.011","volume":"48","author":"G Blanco-Fern\u00e1ndez","year":"2022","unstructured":"Blanco-Fern\u00e1ndez G, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-S\u00e1nchez F, Prieto-Calvo M, Mar\u00edn-Ortega H, S\u00e1nchez-Cab\u00fas S et al (2022) Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID). Eur J Surg Oncol 48:133\u2013141","journal-title":"Eur J Surg Oncol"},{"key":"10359_CR54","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1245\/s10434-014-3821-4","volume":"21","author":"L Schwarz","year":"2014","unstructured":"Schwarz L, Sauvanet A, Regenet N, Mabrut JY, Gigot JF, Housseau E, Millat B, Ouaissi M, Gayet B, Fuks D, Tuech JJ (2014) Long-term survival after pancreatic resection for renal cell carcinoma metastasis. Ann Surg Oncol 21:4007\u20134013","journal-title":"Ann Surg Oncol"},{"key":"10359_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102039","volume":"52","author":"A Rojas-Holgu\u00edn","year":"2024","unstructured":"Rojas-Holgu\u00edn A, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-S\u00e1nchez F, Prieto-Calvo M, Mar\u00edn-Ortega H, S\u00e1nchez-Cab\u00fas S et al (2024) Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: a Spanish multicenter study (PANMEKID). Surg Oncol 52:102039","journal-title":"Surg Oncol"},{"key":"10359_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","volume":"49","author":"W Lu","year":"2019","unstructured":"Lu W, Kang Y (2019) Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell 49:361\u2013374","journal-title":"Dev Cell"},{"key":"10359_CR57","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00345-022-04106-z","volume":"40","author":"D Cignoli","year":"2022","unstructured":"Cignoli D, Fallara G, Aleotti F, Larcher A, Rosiello G, Rowe I, Basile G, Colandrea G, Martini A, De Cobelli F et al (2022) Pancreatic metastases after surgery for renal cell carcinoma: survival and pathways of progression. World J Urol 40:2481\u20132488","journal-title":"World J Urol"},{"key":"10359_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217193","volume":"601","author":"J Qiu","year":"2024","unstructured":"Qiu J, Fu Y, Liu T, Wang J, Liu Y, Zhang Z, Ye Z, Cao Z, Su D, Luo W et al (2024) Single-cell RNA-seq reveals heterogeneity in metastatic renal cell carcinoma and effect of anti-angiogenesis therapy in the pancreas metastatic lesion. Cancer Lett 601:217193","journal-title":"Cancer Lett"},{"key":"10359_CR59","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s42003-024-07004-9","volume":"7","author":"M Roos-Mattila","year":"2024","unstructured":"Roos-Mattila M, Kallio P, Luck TJ, Polso M, Kumari R, Mikkonen P, V\u00e4lim\u00e4ki K, Malmstedt M, Ellonen P, Pellinen T et al (2024) Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma. Commun Biol 7:1355","journal-title":"Commun Biol"},{"key":"10359_CR60","doi-asserted-by":"publisher","first-page":"e134564","DOI":"10.1172\/jci.insight.134564","volume":"5","author":"N Singla","year":"2020","unstructured":"Singla N, Xie Z, Zhang Z, Gao M, Yousuf Q, Onabolu O, McKenzie T, Tcheuyap VT, Ma Y, Choi J et al (2020) Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight 5:e134564","journal-title":"JCI Insight"},{"key":"10359_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10142-023-01113-0","volume":"23","author":"S Lv","year":"2023","unstructured":"Lv S, Tao L, Liao H, Huang Z, Lu Y (2023) Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma. Funct Integr Genomics 23:193","journal-title":"Funct Integr Genomics"},{"key":"10359_CR62","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1111\/jcmm.16479","volume":"25","author":"K Liu","year":"2021","unstructured":"Liu K, Gao R, Wu H, Wang Z, Han G (2021) Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma. J Cell Mol Med 25:4260\u20134274","journal-title":"J Cell Mol Med"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:46:36Z","timestamp":1757205996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["10359"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10359-w","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"38"}}